{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-009967","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.899685+00:00","generated_at":"2026-05-25T12:39:26.774718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M","bullets":["Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.","Full-year net loss $6.4M; adjusted loss $1.0M (excl. $1.3M product acquisition costs).","Cash $18M, total assets $76M, liabilities $53M, shareholders' equity $23M at year-end.","Phase 2 ifetroban DMD study positive top-line; Vibativ approved in China.","Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M in 2024 revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-009967","json":"https://secwatch.observer/filing/0001628280-25-009967.json","markdown":"https://secwatch.observer/filing/0001628280-25-009967.md","text":"https://secwatch.observer/filing/0001628280-25-009967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/0001628280-25-009967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/cpix-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T12:39:26.774718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}